Spyre Therapeutics, Inc. (SYRE:NASDAQ) closed at $92.95 on October 21, 2026, up 1.70% on the day. The stock trades 15.6% below its 52-week high of $110.18 and 339.6% above its 52-week low of $21.15. Over the past year, it gained 318.5%. Spyre Therapeutics, Inc. is part of the Health Care sector.
In 252 trading sessions since October 21, 2025, SYRE closed higher on 135 days (54%). Its best day was April 13, 2026 (+23.36%) and its worst was October 6, 2026 (-13.60%). The stock moved 10% or more in a single session 11 times. It opened at least 5% above the previous day's high 1 time.
Aeglea BioTherapeutics Inc is a clinical-stage biotechnology company. It designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in an early clinical development stage.
Find more stocks like SYRE with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.